欧洲核医学学会关于放射性碘治疗良性甲状腺疾病的指南。
The EANM guideline on radioiodine therapy of benign thyroid disease.
机构信息
Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Unit of Nuclear Medicine, University of Messina, Messina, Italy.
Departments of Radiology and Medicine, MetroHealth Hospital, Case Western Reserve University, Cleveland, OH, USA.
出版信息
Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3324-3348. doi: 10.1007/s00259-023-06274-5. Epub 2023 Jul 3.
Abstract
This document provides the new EANM guideline on radioiodine therapy of benign thyroid disease. Its aim is to guide nuclear medicine physicians, endocrinologists, and practitioners in the selection of patients for radioiodine therapy. Its recommendations on patients' preparation, empiric and dosimetric therapeutic approaches, applied radioiodine activity, radiation protection requirements, and patients follow-up after administration of radioiodine therapy are extensively discussed.
摘要
本文件提供了 EANM 关于良性甲状腺疾病放射性碘治疗的新指南。其目的是为核医学医师、内分泌学家和从业者指导放射性碘治疗患者的选择。它对患者准备、经验性和剂量学治疗方法、应用放射性碘活度、辐射防护要求以及放射性碘治疗后患者随访的建议进行了广泛讨论。
相似文献
1
The EANM guideline on radioiodine therapy of benign thyroid disease.
Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3324-3348. doi: 10.1007/s00259-023-06274-5. Epub 2023 Jul 3.
2
Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
Z Med Phys. 2011 Dec;21(4):258-65. doi: 10.1016/j.zemedi.2011.04.006. Epub 2011 Jun 29.
3
[Radioiodine treatment of benign thyroid diseases].
Orv Hetil. 2006 Sep 17;147(37):1783-9.
4
EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases.
Eur J Nucl Med Mol Imaging. 2013 Jul;40(7):1126-34. doi: 10.1007/s00259-013-2387-x. Epub 2013 Apr 11.
5
Improved Patient Dosimetry at Radioiodine Therapy by Combining the ICRP Compartment Model and the EANM Pre-Therapeutic Standard Procedure for Benign Thyroid Diseases.
Front Endocrinol (Lausanne). 2021 Mar 12;12:634955. doi: 10.3389/fendo.2021.634955. eCollection 2021.
6
[Guideline for radioiodine therapy for benign thyroid diseases (version 4)].
Nuklearmedizin. 2007;46(5):220-3.
7
The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
Clin Endocrinol (Oxf). 1997 Oct;47(4):425-30. doi: 10.1046/j.1365-2265.1997.2741075.x.
8
[Graves' disease nd toxic nodular goiter--radioiodine therapy].
Nuklearmedizin. 2002 Apr;41(2):63-70.
9
[Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
Radiol Med. 2000 Dec;100(6):480-3.
10
Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists.
Clin Endocrinol (Oxf). 2008 May;68(5):814-20. doi: 10.1111/j.1365-2265.2007.03097.x. Epub 2007 Oct 31.
引用本文的文献
1
Development and validation of a nomogram prediction model for factors influencing I-refractory Graves' hyperthyroidism.
Front Endocrinol (Lausanne). 2025 Aug 13;16:1628226. doi: 10.3389/fendo.2025.1628226. eCollection 2025.
2
Low risk of thyroid eye disease (TED) following radioiodine (RAI) therapy in a multidisciplinary setting: a retrospective cohort study.
Thyroid Res. 2025 Aug 14;18(1):41. doi: 10.1186/s13044-025-00259-2.
3
Process to radioactive iodine treatment for Graves' hyperthyroidism: condemned or absolved?
J Endocrinol Invest. 2025 Aug 6. doi: 10.1007/s40618-025-02653-x.
4
2025 Korean Thyroid Association Management Guidelines for Radioactive Iodine Therapy in Patients with Hyperthyroidism.
Endocrinol Metab (Seoul). 2025 Jun;40(3):342-356. doi: 10.3803/EnM.2025.2464. Epub 2025 Jun 24.
5
Sex-Related Differences in Risk Factors Associated With Nonhealing or Recurrence of Hyperthyroidism in Patients With Graves' Disease Treated With Radioactive Iodine.
Health Care Sci. 2025 Jun 13;4(3):188-194. doi: 10.1002/hcs2.70021. eCollection 2025 Jun.
6
The Impact of Radioiodine (131I) Therapy of Thyroid Disease on Salivary Glands Function and Inflammation: A Comprehensive Review.
Biomedicines. 2025 Jun 7;13(6):1404. doi: 10.3390/biomedicines13061404.
7
Challenges in the dose calculation from urine measurements in routine internal monitoring of I and other radionuclides.
Radiat Environ Biophys. 2025 Aug;64(3):409-416. doi: 10.1007/s00411-025-01129-z. Epub 2025 May 27.
8
Primary hyperparathyroidism in a domestic shorthair cat following I radioiodine therapy.
J Small Anim Pract. 2025 Aug;66(8):582-586. doi: 10.1111/jsap.13854. Epub 2025 Apr 1.
9
Radioiodine Therapy of Graves' Disease in Women with Childbearing Potential and the Pre-Conceptional Counseling About Antithyroid Drugs.
J Clin Med. 2025 Feb 28;14(5):1667. doi: 10.3390/jcm14051667.
10
A Method for Calculating Small Sizes of Volumes in Postsurgical Thyroid SPECT/CT Imaging.
Life (Basel). 2025 Jan 29;15(2):200. doi: 10.3390/life15020200.
本文引用的文献
1
2022 European Thyroid Association Guideline for the management of pediatric Graves' disease.
Eur Thyroid J. 2022 Jan 1;11(1):e210073. doi: 10.1530/ETJ-21-0073.
2
A Systematic Review and Meta-Analysis of the Relationship Between the Radiation Absorbed Dose to the Thyroid and Response in Patients Treated with Radioiodine for Graves' Disease.
Thyroid. 2021 Dec;31(12):1829-1838. doi: 10.1089/thy.2021.0302.
3
The Efficacy and Short- and Long-Term Side Effects of Radioactive Iodine Treatment in Pediatric Graves' Disease: A Systematic Review.
Eur Thyroid J. 2021 Jul;10(5):353-363. doi: 10.1159/000517174. Epub 2021 Jul 12.
4
The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67. doi: 10.1530/EJE-21-0479.
5
Is There Any Need for Adjusting I Activity for the Treatment of High Turnover Graves' Disease Compared to Normal Turnover Patients? Results from a Retrospective Cohort Study Validated by Propensity Score Analysis.
Nucl Med Mol Imaging. 2021 Feb;55(1):15-26. doi: 10.1007/s13139-020-00674-3. Epub 2021 Jan 7.
6
Malignancy risk of hyperfunctioning thyroid nodules compared with non-toxic nodules: systematic review and a meta-analysis.
Thyroid Res. 2021 Feb 25;14(1):3. doi: 10.1186/s13044-021-00094-1.
7
Long-Term Outcomes of Radioiodine Therapy for Juvenile Graves Disease with Emphasis on Subsequently Detected Thyroid Nodules: A Single Institution Experience from Japan.
Endocr Pract. 2020 Jul;26(7):729-737. doi: 10.4158/EP-2019-0468. Epub 2020 Nov 24.
8
Personalized management of differentiated thyroid cancer in real life - practical guidance from a multidisciplinary panel of experts.
Endocrine. 2020 Nov;70(2):280-291. doi: 10.1007/s12020-020-02418-x. Epub 2020 Aug 9.
9
Diagnostic Performance of Different Thyroid Imaging Reporting and Data Systems (Kwak-TIRADS, EU-TIRADS and ACR TI-RADS) for Risk Stratification of Small Thyroid Nodules (≤10 mm).
J Clin Med. 2020 Jan 16;9(1):236. doi: 10.3390/jcm9010236.
10
Association of Radioactive Iodine Treatment of Hyperthyroidism With Cancer Mortality: An Unjustified Warning?
J Clin Endocrinol Metab. 2020 Apr 1;105(4). doi: 10.1210/clinem/dgz305.
Zotero 插件